Clinical Trial Update: Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating oxaliplatin and liposomal irinotecan with trastuzumab for HER2-positive disease in advanced esophageal and gastric adenocarc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• Eloxatin (oxaliplatin)
• HERCEPTIN (trastuzumab)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Esophageal Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Status: RECRUITING